MCRB - セレス・セラピュ―ティックス (Seres Therapeutics Inc.) セレス・セラピュ―ティックス

 MCRBのチャート


 MCRBの企業情報

symbol MCRB
会社名 Seres Therapeutics Inc (セレス・セラピュ―ティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 セレス・セラピューティクス(Seres Therapeutics Inc.)はマイクロバイオーム治療プラットフォーム会社である。同社はエコビオティック微生物治療薬という生物薬の開発に従事する。同社の医薬品は、ジビオティック微生物の機能を修復することによって健康を回復するように設計される。同社は、結腸微生物の不全症を治療するエコビオティック・マイクロビオム治療法を開発するために、その微生物治療プラットフォームを実施する。SER-109はクロストリジウム・ディフィシル感染症(CDI)のさらなる再発を防ぐために設計されたリード製品候補である。同社は、主要なCDIの初期再発を防ぐためのSER-262、潰瘍性大腸炎を含む炎症性腸疾患(IBD)を治療するためのSER-287およびSER-301、並びに腸内細菌病原体を治療するためのSER-155を含む他の製品候補を開発する。   セレス・セラピュ―ティックスは米国のマイクロバイオ―ム治療法プラットフォ―ム開発企業。生物学的薬剤を開発し、腸内の微生物群であるマイクロバイオ―ムの機能を元に戻す治療法に取り組む。クロストリジウム・ディフィシル感染症の再発を防ぐSER-109、潰瘍性大腸炎を治療するSER-287、抗生物質抵抗性バクテリアを処理するSER-155を開発する。   Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.
本社所在地 200 Sidney Street - 4th Floor Cambridge MA 02139 USA
代表者氏名 Roger Pomerantz ロジャー・ポメラント
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 617-945-9626
設立年月日 40452
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 138人
url www.serestherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/mcrb
adr_tso
EBITDA EBITDA(百万ドル) -85.82700
終値(lastsale) 6.77
時価総額(marketcap) 276186638.51
時価総額 時価総額(百万ドル) 266.39570
売上高 売上高(百万ドル) 34.65400
企業価値(EV) 企業価値(EV)(百万ドル) 170.32970
当期純利益 当期純利益(百万ドル) -91.59400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Seres Therapeutics Inc revenues increased 42% to $8.6M. Net loss increased 4% to $55.7M. Revenues reflect Collaboration revenue - related party increase of 33% to $8M. Higher net loss reflects Research and development expenses increase of 10% to $43.3M (expense) Interest income decrease of 75% to $349K (income) General and administrative expenses increase of 6% to $13.1M (expense).

 MCRBのテクニカル分析


 MCRBのニュース

   Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection  2021/09/29 18:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI), will be presented at the IDWeek 2021 Virtual Conference (Sept. 29-Oct. 3). The Company will be presenting seven posters and oral presentations related to SER-109 and C. difficile, including a late-breaker, as well as
   Why Seres Therapeutics Stock Is Soaring Today  2021/09/15 19:35:13 The Motley Fool
The company completed its target enrollment in a pivotal clinical study.
   Human Microbiome Market Skyrocketing Revenue Growth of US$ 2,921.68 million by 2028 with Profiling Companies- MaaT Pharma, Eligo Bioscience Merck & Co. Inc, AOBiome LLC, Kaleido, Seres Therapeutics  2021/09/15 12:50:44 OpenPR
The Human Microbiome Market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 20212028. The human microbiota consists of the trillions of symbiotic microbial
   Seres Therapeutics achieves enrollment of 300 subjects in SER-109 extension study for C. difficile infection  2021/09/15 12:46:12 Seeking Alpha
   Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection  2021/09/15 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has achieved enrollment of 300 subjects with the ECOSPOR IV open-label study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). The target enrollment of a minimum of 300 subjects for the SER-109 safety database was reached in conjunction with a prior completed Phase 3 study, ECOSPOR lll. Seres is re
   Latest Business Intelligence Solution For The Human Microbiome Industry | Major Player Analysis Vedanta, Seres Therapeutics, Second Genome, Rebiotix, ActoGeniX, etc.  2021/07/07 12:22:05 Tramways Monthly
Industry Growth Insights (IGI) has released their new Human Microbiome Market research report and forecasts for the industry for next eight years. The company predicts that by 2028, there will be a XX% increase in global demand and market will grow with a CAGR of XX%. With this forecast, the future of Human Microbiome market []
   Seres inks deal for C. diff drug with Nestlé  2021/07/02 17:45:13 MarketWatch
Shares of Seres Therapeutics Inc. were down 4.9% in trading on Friday, the day after the company said it plans to jointly commercialize an experimental C. diff drug with Nestlé''s health business. The still-investigational therapy, SER-109, is a microbiome treatment that aims to address recurrent Clostridioides difficile infections, which are the leading cause of hospital-acquired infections in the U.S. As part of the deal, Aimmune Therapeutics, which Nestlé acquired last year, will lead commercialization for Nestlé Health Science, and Seres will receive up to $300 million, based in part on milestones. Canaccord Genuity analyst John Newman said he expects the SER-109 to get U.S. approval sometime this year. Seres'' stock is down 12.6% for the year. The S&P 500 is up 14.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
   Seres, Nestlé to commercialise oral microbiome therapeutic in Canada and US  2021/07/02 14:49:56 Pharmaceutical Business Review
Seres Therapeutics and Nestlé Health Science have signed an agreement to jointly commercialise SER-109, an investigational oral microbiome therapy, in the US and Canada. SER-109 has been developed The post Seres, Nestlé to commercialise oral microbiome therapeutic in Canada and US appeared first on Pharmaceutical Business review .
   Microbiome startup Seres Therapeutics expands Nestlé Health partnership  2021/07/02 09:25:00 Business Journals
As microbiome startup Seres Therapeutics gets ready to bring its C. difficile treatment to the FDA, it has expanded its partnership with Nestlé Health, which is providing Seres with up to $500 million to commercialize the drug. $MCRB
   Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases  2021/07/01 15:01:26 Benzinga
Seres Therapeutics Inc (NASDAQ: MCRB ) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109 is an oral, live microbiome therapy under development for patients with recurrent C. difficile infection, a leading cause of hospital-acquired infections in the U.S. The candidate is made up of purified Firmicutes spores, a type of bacteria. Under the new deal, Nestlés global Full story available on Benzinga.com
   Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference  2021/03/12 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, announced that managment will present a corporate overview at the 31st Annual Oppenheimer Healthcare Conference on Tuesday, March 16 at 9:20 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived
   H.C. Wainwright Stick to Their Buy Rating for Seres Therapeutics By Investing.com  2021/03/08 14:55:01 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Seres Therapeutics
   Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates  2021/03/02 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2020 financial results and provided business updates. “Seres continues to make progress executing against our top corporate priorities. We are enrolling our open label study to support a Biologics License Application (BLA) for SER-109, a potential first-ever FDA approved microbiome therapeutic. We have also advanced our clinical pipe
   Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis  2021/03/02 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that the Company has achieved target enrollment of the Phase 2b ECO-RESET clinical study of SER-287 in patients with mild-to-moderate ulcerative colitis (UC) in both the U.S. and Canada. SER-287, Seres’ second microbiome therapeutic to reach late-stage clinical trials following a successful Phase 3 readout for SER-109, could represent a new therapeutic paradigm for UC by targeting underlying biological dr
   Seres Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/01 23:55:00 Stock Market Daily
Seres Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セレス・セラピュ―ティックス MCRB Seres Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)